Author: Luisa Lundin, PhD, Alliance and Communications Manager, NorthX Biologics
Published by BioPharm International May 2026
Translating advanced therapy medicinal products (ATMPs) from early research into robust, GMP-compliant manufacturing remains one of the key challenges in bringing new therapies to patients. The “translation gap” between discovery and scalable production can determine the success or failure of a program, making early decision-making, process understanding, and collaboration critical.
In BioPharm International (May 15, 2026), Luisa Lundin outlines how this gap can be reduced through earlier integration of manufacturing considerations and closer collaboration between developers and CDMOs. The article provides practical perspectives on how to move from promising research to scalable, reliable production.
Read the full article: Translational Intelligence: The CDMO’s Unspoken Role in the ATMP Journey